<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363945</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-101-MLK</org_study_id>
    <nct_id>NCT03363945</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants</brief_title>
  <official_title>A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medeor Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medeor Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety and efficacy of cellular
      immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of
      human leukocyte antigen (HLA)-matched, living donor kidney transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients receiving a transplanted kidney are required to take life-long
      immunosuppressive medications to prevent rejection of the transplanted kidney. These
      medications carry substantial side effects. In addition, these medicines often do not
      completely control damage to the kidney from the recipients' immune system, ultimately
      causing the kidney to fail.

      Medeor Therapeutics is developing a novel cell-based therapy to reprogram the recipients'
      immune system to accept a transplanted kidney without the need for long term use of
      immunosuppression drugs.

      The purpose of the current Phase 3 study is to demonstrate the efficacy and safety of MDR-101
      for the induction of transplant immune tolerance in a prospective, randomized, multicenter
      clinical trial. MDR-101 is intended to induce mixed lymphohematopoietic chimerism and donor
      specific immune tolerance in order to preserve transplant kidney function, avert transplant
      kidney rejection, and eliminate the cumulative and serious side effects associated with
      immunosuppressive drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Total lymphoid irradiation and anti-thymocyte globulin</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional immune tolerance defined as</measure>
    <time_frame>Up to 36 months post-kidney transplant</time_frame>
    <description>Achievement of the required duration of persistent donor mixed chimerism to permit calcineurin inhibitor immunosuppressive withdrawal beginning at 6-7 months post-kidney transplant surgery, and
Successful withdrawal from all immunosuppressives by at least 12 months post-kidney transplant surgery, and
Subsequent successful maintenance off all immunosuppressive drugs for at least 24 additional months (out to at least 36 months post-kidney transplant surgery) without biopsy-proven acute rejection, de novo Donor Specific Antibody, transplant kidney loss, or subject death. Loss to follow-up will be adjudicated as a failure in intent-to-treat analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>MDR-101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose will be administered via IV infusion post-kidney transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDR-101</intervention_name>
    <description>Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells</description>
    <arm_group_label>MDR-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:

          -  Planned recipient of a first kidney allograft from an HLA-matched, living related
             donor

          -  Age ≥18 and ≤65 years

          -  Single solid organ recipient (kidney only)

          -  ABO compatibility with donor

        Recipient Exclusion Criteria:

          -  Underlying kidney disease with a high risk of disease recurrence in the transplanted
             kidney

          -  Baseline positive donor-specific anti-HLA antibody testing

          -  Is taking immunosuppressive therapy

          -  Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)

        Donor Inclusion Criteria:

          -  HLA-matched first degree (parent, child or sibling) or second-degree (child of a
             sibling) relative of the prospective recipient participant

          -  Age ≥18 and ≤65 years

          -  Prepared to be a living related kidney donor, and capable of undergoing G-CSF
             mobilization and apheresis of hematopoietic cells

        Donor Exclusion Criteria:

          -  History of autoimmune disorders

          -  History of type 1 or type 2 diabetes mellitus

          -  Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV

          -  History of infection with Zika virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Scott Batty, Jr., MD</last_name>
    <role>Study Director</role>
    <affiliation>Medeor Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonia Martinez, MBA</last_name>
    <phone>650-810-0464</phone>
    <email>smartinez@medeortherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Wiseman, MD</last_name>
      <phone>720-848-2237</phone>
      <email>alexander.wiseman@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janis Cicerchi</last_name>
      <phone>303-724-0183</phone>
      <email>janis.cicerchi@ucdenver.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Chandraker, MD</last_name>
      <phone>617-732-5259</phone>
      <email>achandraker@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Conte</last_name>
      <phone>617-525-8003</phone>
      <email>sconte.@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anil Chandraker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan McDermott, RN</last_name>
      <phone>617-632-9841</phone>
      <email>smcderm2@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Helzer</last_name>
      <phone>617-632-9919</phone>
      <email>chelzer@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Group</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Rajab, MD</last_name>
      <phone>614-261-1141</phone>
      <email>amer.rajab@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Holloway</last_name>
      <phone>614-293-4665</phone>
      <email>brittany.holloway@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashesh Shah, MD</last_name>
      <phone>317-496-7944</phone>
      <email>ashesh.shah@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dee Rinaldi</last_name>
      <phone>215-503-1765</phone>
      <email>dee.rinaldi@jefferson.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Bingaman, MD</last_name>
      <phone>210-575-8400</phone>
      <email>adam.bingaman@mhshealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Wilma Cain</last_name>
      <phone>210-575-6026</phone>
      <email>wilma.cain@mhshealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intermountain Transplant Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Titte Srinivas, MD</last_name>
      <phone>801-507-8330</phone>
      <email>titte.srinivas@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Jake Krong</last_name>
      <phone>801-507-9333</phone>
      <email>Jake.Krong@imail.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dixon B Kaufman, MD</last_name>
      <phone>312-908-2000</phone>
      <email>kaufman@surgery.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristi Schneider, RN MSN ANP</last_name>
      <phone>608-263-7064</phone>
      <email>schneide@surgery.wisc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>cellular therapy</keyword>
  <keyword>anti-rejection therapy</keyword>
  <keyword>living donor</keyword>
  <keyword>HLA-matched</keyword>
  <keyword>hematopoietic stem cells (HSC)</keyword>
  <keyword>CD34+</keyword>
  <keyword>CD3+</keyword>
  <keyword>T cells</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

